A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. Most meningiomas (90 percent) are categorized as benign tumors, with the remaining 10 percent being atypical or malignant. In many cases, benign meningiomas grow slowly. This means that depending upon where it is located, a meningioma may reach a relatively large size before it causes symptoms. Meningiomas account for about 27 percent of primary brain tumors, making them the most common tumor of that type. With May marking Brain Tumor Awareness Month, we’re looking at some common questions about …
Every year, about 4,700 children in the United States are diagnosed with brain cancer – making it the most common solid tumor in children. It is also one of the most difficult cancers to treat. Brain tumors are the leading cause of cancer-related deaths in children under age 10 and the second leading cause of cancer deaths in people under 20. Although survival rates for children with some types of brain tumors have risen over the past 30 years, current research aims to increase those rates dramatically in the years ahead. Scientists are focusing on the basic genetic and genomic …
Dana-Farber Cancer Institute recently partnered with CancerConnect and Lakshmi Nayak, MD, to answer questions about brain cancer. Nayak is a neuro-oncologist in the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and an instructor in neurology at Harvard Medical School. Q: There seems to be some progress concerning treatment of brain tumors, especially immunotherapy. Do you think we will see further advancements in that area, or in other areas? A: Immunotherapy is indeed a hot topic in gliomas. This is largely driven by advances we have seen in the treatment of melanoma. The way these drugs work is to …
The drug Avastin, when added to initial therapy for glioblastoma, can give patients a few extra months’ reprieve before their brain tumors start growing again, but does it make their quality of life better – or worse? That’s a matter of heated debate for doctors – and confusion for patients – after two large clinical trials reported conflicting results at the annual American Society of Clinical Oncology (ASCO) conference in June. Some experts contend that Avastin lacked sufficient benefit for use as an “upfront” treatment for glioblastomas – the most common and aggressive brain tumors.
by Richard Saltus People experiencing an unusual or particularly bad headache sometimes worry they might have a brain tumor. Headaches are very common and usually don’t signal a serious illness – but when should you be checked out by a doctor? We asked neuro-oncologists Lakshmi Nayak, MD, and Eudocia Quant Lee, MD, MPH from the Dana-Farber Center for Neuro-Oncology to review the red flags that warrant a medical follow up:
by Robert Levy More than 18,000 cancer scientists from around the world are in Washington, D.C., this week for the annual meeting of the American Association for Cancer Research (AACR). The meeting serves as a forum for the presentation and discussion of the latest discoveries in cancer research. The meeting coincides with the Rally for Medical Research, which was held Monday morning on the steps of the Carnegie Library in the nation’s capital.
A tumor is an abnormal mass of tissue that has formed a lump. It’s called benign if it grows slowly and is self-limiting; that is, if it doesn’t have the capacity to invade nearby tissues and spread beyond its original site. A malignant, or cancerous, tumor, on the other hand, is innately dangerous because its cells can divide uncontrollably and produce virtually immortal daughter cells. Malignant tumor cells can penetrate and destroy adjacent tissue, and can metastasize, or travel through the circulation to distant parts of the body and form new tumors.
Musician Sheryl Crow announced on June 5 that she has a benign brain tumor known as a meningioma. Below, doctors from Dana-Farber’s Center for Neuro-Oncology describe this condition. The singer-songwriter, a breast cancer survivor, visited Dana-Farber in 2006. Meningiomas are tumors on the surface of the brain, spinal cord, and fluid spaces. They are the most common type of brain tumor, with approximately 55,000 new cases diagnosed annually in the United States.
Hilary Olson had no reason to suspect that her daughter Hailey might have a brain tumor. “Her smile was starting to droop a little, and one of her eyes was a little jumpy,” says the 6-year-old’s mother. “We took her to see a neurologist, and he thought she might have pinched a nerve. “But when he sent us to Boston Children’s Hospital for an MRI,” she continues, “the radiologists sent us straight down to the emergency room.”
More than 600,000 people in the United States are living with a primary brain tumor — one that begins and stays in the brain — and over 60,000 adults and children will be diagnosed with a brain tumor this year. In recognition of May as Brain Tumor Awareness Month, we asked David Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, for the latest advances in brain tumor research and patient care.